{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:35:10Z","timestamp":1793198110586,"version":"4.5.0"},"reference-count":37,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2706503"],"award-info":[{"award-number":["2023YFC2706503"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["J230009"],"award-info":[{"award-number":["J230009"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["Z231100003923004"],"award-info":[{"award-number":["Z231100003923004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["2023YFC2706503"],"award-info":[{"award-number":["2023YFC2706503"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["J230009"],"award-info":[{"award-number":["J230009"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["Z231100003923004"],"award-info":[{"award-number":["Z231100003923004"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Municipal Science &amp; Technology Commission","award":["2023YFC2706503"],"award-info":[{"award-number":["2023YFC2706503"]}]},{"name":"Beijing Municipal Science &amp; Technology Commission","award":["J230009"],"award-info":[{"award-number":["J230009"]}]},{"name":"Beijing Municipal Science &amp; Technology Commission","award":["Z231100003923004"],"award-info":[{"award-number":["Z231100003923004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Purpose: Currently, there is no clinical data reported on the therapy of dual biological agents in pediatric-onset inflammatory bowel disease (PIBD) patients in China. The purpose of this study was to evaluate the efficacy and safety of dual biologic therapy or biologics combined with small molecule drugs in refractory PIBD patients in China. Methods: Clinical, laboratory, endoscopic, and ultrasound data of PIBD patients from the Department of Gastroenterology of Beijing Children\u2019s Hospital between January 2021 and October 2024 were retrospectively analyzed. PIBD patients who received dual biologic treatment or a combination of biologic and small molecule therapy were included in this study. Steroid-free clinical remission and adverse events were recorded. Results: In this retrospective study, out of 520 children with IBD, twelve children (2.3%) were diagnosed with refractory PIBD and met the criteria for dual biotherapy, including four with UC (33%) and eight with CD (67%). The median age of patients was 13.64 (range, 1.2\u201317.1) years at eligibility for dual biologic therapy. There are eight (67%) patients treated with infliximab\/ustekinumab (IFX + UST), three (25%) patients with upadacitinib\/ustekinumab (UPA + UST), one (8%) patient with infliximab\/vedolizumab (IFX + VDZ). At 3, 6, and 12 months of dual biological treatment, 91.2% (11\/12), 100% (12\/12), and 100% (12\/12) patients showed steroid-free clinical remission, respectively. The median fecal calprotectin decreased significantly from 1852.5 \u00b5g\/g (IQR, 762.5\u20131988.25) at baseline to 359.0 (IQR, 217.5\u2013730.25) \u03bcg\/g at 3 months, 113 (IQR, 73.7\u2013256) \u03bcg\/g at 6 months, and 82.5 (IQR, 40.25\u2013122.25) \u03bcg\/g at 12 months. Only one CD patient with IFX + UST reported mild elevation of aminotransferase, who recovered after symptomatic treatment. Conclusions: Dual biologic or small molecule therapy may be effective and safe for children with refractory PIBD in China.<\/jats:p>","DOI":"10.3390\/children12010075","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T07:59:42Z","timestamp":1736409582000},"page":"75","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dual Biologic or Small Molecule Therapy in Pediatric Inflammatory Bowel Disease: A Single Center Experience"],"prefix":"10.3390","volume":"12","author":[{"given":"Cheng","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health, No. 56 Nanlishi Road, Xicheng District, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health, No. 56 Nanlishi Road, Xicheng District, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health, No. 56 Nanlishi Road, Xicheng District, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health, No. 56 Nanlishi Road, Xicheng District, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wang, Y., Pan, C.W., Huang, Y., Zheng, X., Li, S., He, M., Hashash, J.G., Farraye, F.A., and Ehrlich, A.C. (2024). Global Epidemiology and Geographic Variations of Pediatric-Onset Inflammatory Bowel Disease: A Comprehensive Analysis of the Global Burden of Disease Study 1990 to 2019. Inflamm. Bowel Dis., izae093.","DOI":"10.1093\/ibd\/izae093"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ped4.12144","article-title":"Disease spectrum analysis of hospitalized children in China: A study of 18 tertiary children\u2019s hospitals","volume":"3","author":"Feng","year":"2019","journal-title":"Pediatr. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn\u2019s disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Honap","year":"2023","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/jgh.16097","article-title":"Medical Management of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group","volume":"38","author":"Lee","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The Medical Management of Paediatric Crohn\u2019s Disease: An ECCO-ESPGHAN Guideline Update","volume":"15","author":"Aloi","year":"2021","journal-title":"J. Crohns. Colitis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MPG.0000000000001672","article-title":"Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience","volume":"66","author":"Debruyn","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","article-title":"Real World Experience with Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center","volume":"69","author":"Dayan","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ecco-jcc\/jjy206","article-title":"Management of Paediatric Patients with Medically Refractory Crohn\u2019s Disease Using Ustekinumab: A Multi-Centred Cohort Study","volume":"13","author":"Chavannes","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.dld.2018.07.040","article-title":"Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-the Israeli real world experience","volume":"51","author":"Kopylov","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: Recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jpr3.12067","article-title":"Rescue therapy with upadacitinib in medically refractory pediatric ulcerative colitis","volume":"5","author":"Miller","year":"2024","journal-title":"JPGN Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yerushalmy-Feler, A., Spencer, E.A., Dolinger, M.T., Suskind, D.L., Mitrova, K., Hradsky, O., Conrad, M.A., Kelsen, J.R., Uhlig, H.H., and Tzivinikos, C. (2024). Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multi-center Study. J. Crohns Colitis, jjae182.","DOI":"10.1093\/ecco-jcc\/jjae182"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Runde, J., Ryan, K., Hirst, J., Lebowitz, J., Chen, W., Brown, J., and Strople, J. (2024). Upadacitinib is associated with clinical response and steroid-free remission for children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr., 1\u20138.","DOI":"10.1002\/jpn3.12408"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113544","DOI":"10.1016\/j.intimp.2024.113544","article-title":"Novel targets for mucosal healing in inflammatory bowel disease therapy","volume":"144","author":"Mansouri","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/ibd\/izab028","article-title":"Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?","volume":"27","author":"Judge","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ibd\/izad064","article-title":"Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN","volume":"30","author":"Olbjorn","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1007\/s10620-024-08379-9","article-title":"Real-World Outcomes of Dual Advanced Therapy in Children and Young Adults with Inflammatory Bowel Disease","volume":"69","author":"Kellar","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109545","DOI":"10.1016\/j.intimp.2022.109545","article-title":"Combination therapy in inflammatory bowel disease: Current evidence and perspectives","volume":"114","author":"Dai","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106935","DOI":"10.1016\/j.phrs.2023.106935","article-title":"Dual biological therapy and small molecules in pediatric inflammatory bowel disease","volume":"196","author":"Penagini","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/ibd\/izae020.193","article-title":"Systematic review with meta-analysis: Safety and effictiveness of combining biologics and small molecules in inflmammatory bowel disease","volume":"30","author":"Osman","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_23","unstructured":"The Subspecialty Group of Gastroenterology, the Society of Pediatrics, Chinese Medical Association, and The Subspecialty Group of Clinical Nutrition, the Society of Pediatrics, Chinese Medical Association (2019). Expert consensus on the diagnosis and management of pediatric inflammatory bowel disease. Chin. J. Pediatr., 57, 501\u2013507."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MPG.0b013e3181d13609","article-title":"Development and Assessment of a Modified Pediatric Crohn Disease Activity Index","volume":"51","author":"Leach","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MPG.0b013e31825959b8","article-title":"Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations","volume":"55","author":"Rufo","year":"2012","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: The SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest. Endosc."},{"key":"ref_28","first-page":"263","article-title":"Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)","volume":"79","author":"Dignass","year":"2014","journal-title":"Rev. Gastroenterol. Mex."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ecco-jcc\/jjab173","article-title":"Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement","volume":"16","author":"Ilvemark","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jpn3.12179","article-title":"Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period","volume":"79","author":"Wlazlo","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40272-023-00579-6","article-title":"Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review","volume":"25","author":"Brauner","year":"2023","journal-title":"Paediatr. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MEG.0000000000002203","article-title":"Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn\u2019s disease in children","volume":"34","author":"Howard","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Levine, A.E., Mark, D., Smith, L., Zheng, H.B., and Suskind, D.L. (2023). Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030969"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ibd\/izad300","article-title":"Single-center Experience with Upadacitinib for Adolescents with Refractory Inflammatory Bowel Disease","volume":"30","author":"Spencer","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_36","first-page":"1928","article-title":"Transmural healing evaluated by bowel sonography in patients with Crohn\u2019s disease on maintenance treatment with biologics","volume":"19","author":"Castiglione","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"otae029","DOI":"10.1093\/crocol\/otae029","article-title":"Economics of Emergency Department Visits by Patients with Inflammatory Bowel Disease: A Real-World Analysis","volume":"6","author":"Clarke","year":"2024","journal-title":"Crohns Colitis 360"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/1\/75\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:25:27Z","timestamp":1759919127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/1\/75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["children12010075"],"URL":"https:\/\/doi.org\/10.3390\/children12010075","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}